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Abstract
Background: High tumour stromal content has been found to predict adverse clinical outcome in a range of
epithelial tumours. The aim of this study was to assess the prognostic significance of tumour-stroma ratio (TSR) in
endometrial adenocarcinomas and investigate its relationship with other clinicopathological parameters.
Methods: Clinicopathological and 5-year follow-up data were obtained for a retrospective series of endometrial
adenocarcinoma patients (n = 400). TSR was measured using a morphometric approach (point counting) on
digitised histologic hysterectomy specimens. Inter-observer agreement was determined using Cohen’s Kappa
statistic. TSR cut-offs were optimised using log-rank functions and prognostic significance of TSR on overall survival
(OS) and disease-free survival (DFS) were determined using Cox Proportional Hazards regression analysis and
Kaplan-Meier curves generated. Associations of TSR with other clinicopathological parameters were determined
using non-parametric tests followed by Holm-Bonferroni correction for multiple comparisons.
Results: TSR as a continuous variable associated with worse OS (P = 0.034) in univariable Cox-regression analysis.
Using the optimal cut-off TSR value of 1.3, TSR-high (i.e. low stroma) was associated with worse OS (HR = 2.51; 95 %
CI = 1.22–5.12; P = 0.021) and DFS (HR = 2.19; 95 % CI = 1.15–4.17; P = 0.017) in univariable analysis. However, TSR did
not have independent prognostic significance in multivariable analysis, when adjusted for known prognostic
variables. A highly significant association was found between TSR and tumour grade (P < 0.001) and lymphovascular
space invasion (P < 0.001), both of which had independent prognostic significance in this study population.
Conclusions: Low tumour stromal content associates with both poor outcome and with other adverse prognostic
indicators in endometrial cancer, although it is not independently prognostic. These findings contrast with studies
on many - although not all - cancers and suggest that the biology of tumour-stroma interactions may differ
amongst cancer types.
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Background
Endometrial cancer (EC) is the most prevalent gynaeco-
logical malignancy in the Western world and ranks as
the ninth commonest cause of cancer-related mortality
in women in the UK [1]. Moreover, the incidence of
endometrial cancer in the UK has increased by 43 % in
15 years since 1993–1995, which has been accompanied
by a 14 % increase in the number of EC-related deaths
[2]. ECs are broadly categorised into types I and II on
the basis of aetiology, histology and clinical behaviour
[3, 4]. Type I (circa 80 % of cases) is represented by
endometrioid endometrial carcinomas (EECs) which
are typically oestrogen-dependent malignancies typic-
ally arising from a background of atypical hyperplasia.
These tend to occur in younger, peri-menopausal
women and generally have a more favourable out-
come [4–7]. Most of the remaining 20 % of ECs are
type II, high-grade, non-endometrioid endometrial
cancers (NEECs) which are most commonly represented
by serous and clear cell carcinomas. NEECs are thought
to arise from a precursor intraepithelial carcinomatous
lesion in a background of endometrial atrophy. These
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cancers tend to affect older, post-menopausal women, fol-
low a more aggressive clinical course and have a much
poorer prognosis [5]. However, this classification model is
an over-simplification since many endometrial cancers are
not categorised neatly according to this dichotomy. In-
deed, poorly differentiated, high grade EECs are frequently
grouped with the NEECs for the purpose of treatment due
to their poorer outcome, although their prognosis in com-
parison to classical NEECs is debated [8–11]. Moreover, a
large proportion of NEECs (circa 40 %) are of mixed sub-
type and can have endometrioid features [5]. Finally, the
comparatively poor prognosis of low grade EECs arising in
a background of atrophic endometrium present further
difficulties for the Type I/II system [12]. Thus, there is a
need to identify additional prognostic markers to achieve
better patient stratification in the clinical management of
endometrial cancer.
Malignant epithelial tumours are composed of carcin-
oma cells, together with stromal fibroblasts, immune
effector cells, microvasculature and the extracellular
matrix, which are collectively referred to as the tumour
microenvironment. The dynamic interplay between
cancer cells and stromal components within the
tumour microenvironment contributes to malignant
progression and metastasis [13]. As such, tumour-
associated stroma has potential as both a target for
novel therapies and utility in prognostication. A num-
ber of studies have identified tumour-stroma ratio
(TSR) as having independent prognostic significance,
where high stromal content has been shown to predict
adverse outcome in a range of malignancies [14–27], al-
though the prognostic significance of tumour stromal
content in endometrial cancer remains to be deter-
mined. The purpose of this study was therefore to de-
termine the prognostic significance of TSR and its
association with other clinicopathological variables in a
large series of surgically treated endometrial cancer
patients, where TSR was assessed objectively using a
digitised virtual scoring system.
Methods
Patients
This study received ethical approval from Leeds NRES
committee (Ref: 05/Q1107/41). Patients gave their writ-
ten informed consent for their tissue samples to be used
in research. Clinicopathological and follow-up data were
collected for a retrospective series of 400 women in the
Yorkshire area (UK) diagnosed with endometrial adeno-
carcinoma between 2005 and 2007 who had undergone
a hysterectomy at our tertiary referral centre (St James’s
University Hospital). Median follow-up was 79.7 months
(reverse Kaplan-Meier method). For both overall survival
(OS) and disease-free survival (DFS), patients were cen-
sored at end of follow-up. OS was defined as time from
diagnosis to death and DFS was defined as time from
diagnosis to recurrence or death. Staging data were con-
verted from the International Federation of Gynaecology
and Obstetrics (FIGO) 1988 to the FIGO 2009 staging
system [28] according to individual patients’ pathology
reports.
Morphometric assessment of tumour-stroma ratio
For each patient, 2 representative slides of 4 μm haema-
toxylin and eosin-stained tissue sections were selected
and subjected to mark-up by a histopathologist (NMO).
Areas selected for mark-up were from the superficial re-
gion, as in [17], in order to standardise sampling for all
tumours since not all cases had significant myometrial
invasion. Areas of overt necrosis and where tumour
mass was poorly preserved were avoided. Each slide was
scanned at 20× magnification using digital slide scanners
(Aperio XT Aperio Technologies, Vista, CA, USA and
hosted on the University of Leeds digital slide servers.
An area of 9 mm2 (±0.25 mm2) was sampled from one
slide for each patient using a digital slide viewer (Image-
Scope, Version 8.0, Aperio Technologies). In each in-
stance, the slide that most accurately represented the
tumour mass was used; in cases where more than one
histological type was observed, multiple areas were
marked up and sampled in order to obtain representa-
tive measures of tumour heterogeneity. Similarly, in
large tumour masses where there could be variation in
proportion of tumour and stroma, at least three 9 mm2
areas were defined. Virtual graticule software (Random-
Spot) [29] was used to superimpose 300 (±15 %) system-
atic random points onto the selected area (Fig. 1); this
number of measurement points has previously been
optimised in other studies [17, 30]. The categories used,
as devised by West and colleagues [17], were: unin-
formative (unclassifiable), tumour (viable cancer cell),
stroma/fibrosis, necrosis, vessel, inflammation, tumour
lumen (surrounded by tumour cells on all sides), mucus
and smooth muscle. Retraction artefacts were classified
in one of two ways: if the surrounding areas were the
same histological category, i.e. retraction between two
areas of stroma, then the retraction point was classified
as that component. If the retraction artefact was
between different histological categories i.e. between
stroma and tumour, the retraction was classified as unin-
formative. Any tumour cells in areas of necrosis or lu-
menal debris were coded as necrosis. In areas of poor
preservation where there was tumour breakdown, any
debris or ‘white space’ were recorded as uninformative
while clusters of viable cancer cells were recorded as
tumour. Training for tumour scoring was provided by
NMO and 20 cases were independently double-scored
(HP and NMO). As inter-observer agreement between
the two observers’ classifications was very high (κ = 0.94;
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see Statistical Analysis), the remainder of the cases were
scored by one observer (HP).
Cases were marked up and scored with the observer
blinded to the outcome data. Totals for each scoring cat-
egory were generated and TSR was calculated by divid-
ing the total tumour count over the total stroma count
for each case.
Statistical analysis
Inter-observer agreement on point classification (tumour,
stroma etc.) was assessed using Cohen’s Kappa statistic.
TSR was log-transformed prior to analysis to allow identi-
cal inferences for both tumour and stroma content to be
made. Time-dependent survival analysis was used to opti-
mise the TSR cut-off using coxph and survfit functions in
the R package Survival, whereby the optimal cut-off gave
the lowest log-rank P value. The prognostic significance of
TSR, both as a continuous variable and using the TSR
cut-off, on OS and DFS was determined using Cox Pro-
portional Hazards regression analysis in R [31]. Kaplan-
Meier analysis was conducted using IBM SPSS (ver-
sion 21) and curves were visualised using Graphpad
Prism (version 6). Associations of TSR with other
clinicopathological variables were determined in SPSS
using Mann–Whitney U tests or Kruskal-Wallis tests
followed by Mann–Whitney-U post-hoc tests, as appropri-
ate. Corrections for multiple comparisons were performed
using Holm’s sequential Bonferroni method.
Results
Patient characteristics
Patient characteristics are summarised in Table 1.
Median age at diagnosis was 66 years (range 28–95). In
addition to total hysterectomy and bilateral salpingo-
oophorectomy, 35 % of patients also underwent omental
biopsy/omentectomy and 81 % had lymphadenec-
tomy (pelvic/para-aortic). Following post-operative
staging, 36 % of patients received adjuvant radiotherapy
Table 1 Summary of clinicopathological data for the patient
cohort
Clinicopathological data Median (range)
Age (years) at diagnosis 66 (28–95)
N (%)
Histopathological subtype
Endometrioid 302 (75.5)
Serous 34 (8.5)
Clear cell 11 (2.8)
Mixed 50 (12.5)
Undifferentiated 1 (0.25)
Mucinous 2 (0.5)
Surgical stage (FIGO 2009)
I 262 (65.5)
II 39 (9.8)
III 75 (18.8)
IV 24 (6.0)
Grade
1 149 (37.25)
2 106 (26.5)
3 145 (36.25)
Type of surgery
Total abdominal hysterectomy 345 (86.3)
Laparoscopic assisted vaginal hysterectomy 55 (13.8)
Bilateral salpingo-oophorectomy 391 (97.8)
Lymphadenectomy 324 (81.0)
Omental biopsy 50 (12.5)
Omentectomy 89 (22.5)
Adjuvant therapy
Radiotherapy alone 98 (24.5)
Chemotherapy alone 17 (4.25)
Radiotherapy + chemotherapy 45 (11.25)
No adjuvant treatment 240 (60)
Abbreviation: FIGO international federation of gynaecology and obstetrics
Fig. 1 Morphometric assessment of tumour-stroma ratio. (a) Selection
of a 9 mm2 area from a haematoxylin and eosin-stained representative
section of endometrial cancer. A total of 300 points are randomly
inserted into the selected area. (b) Annotation of individual points
comprising tumour (T), stroma (S) and necrosis (N)
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(brachytherapy and/or external beam radiotherapy) and
16 % of patients received adjuvant chemotherapy (pacli-
taxel and carboplatin combination therapy). None re-
ceived neoadjuvant chemo/radiotherapy. The majority of
patients (76 %) were diagnosed at early stage (I/II) and
EEC was the predominant (76 %) histopathological sub-
type. There were 65 recurrences and 122 deaths during
the follow-up period. The estimated cumulative 5-year
survival for this patient cohort was 73.0 ± 0.02 % and
70.0 ± 0.02 % for OS and DFS, respectively.
Tumour-stroma ratio and cut-off determination
Including all histological types, the median percentage
fraction of tumour was 66.0 % (range 12.7–92.2 %)
whilst the median percentage fraction of stroma was
20.1 % (range 2.0–81.2 %). The median TSR was 3.3
(range 0.16–45.20). TSR cut-off optimisation identified a
TSR cut-off of 1.3 for OS which, in an idealised sample
with only tumour and stroma scores, would correspond
to a tumour-stroma ratio of 56.5 %:43.5 %. Representa-
tive images of TSR low and TSR high tumours are
depicted in Fig. 2.
Increased TSR associates with adverse prognosis in
univariable analysis
Prognostic parameters for univariable analysis included
age, FIGO 2009 stage, grade, and the presence of
lymphovascular space invasion, a known independent
prognostic indicator for endometrial cancer [32]. Depth
of myometrial invasion, cervical involvement and lymph
node status form part of the FIGO staging system and,
as such, were not included as independent variables in
the analysis. Univariable Cox proportional hazards ana-
lysis of logTSR as a continuous variable showed that in-
creased TSR was significantly associated with worse OS
(P = 0.032) and showed a trend towards associating with
poorer DFS (P = 0.058) (Table 2). Kaplan-Meier analysis
Fig. 2 Representative examples of TSR-low and TSR-high endometrial
cancer specimens. Haematoxylin and eosin-stained sections of
(a) TSR-low and (b) TSR-high EEC cases
Table 2 Univariable survival analysis of TSR and other prognostic factors
Overall survival Disease-free survival
Factor HR (95 % CI) P HR (95 % CI) P
LogTSR (continuous) 1.75 (1.04–2.94) 0.034 1.61 (0.98–2.64) 0.058
TSR ( ≥1.30 vs. <1.30) 2.51 (1.22–5.14) 0.012 2.18 (1.15–4.16) 0.017
Age (continuous) 1.07 (1.05–1.09) <0.001 1.06 (1.05–1.08) <0.001
Stage (FIGO 2009)
I Referent Referent Referent Referent
II 1.83 (1.00–3.36) 0.051 1.69 (0.94–3.01) 0.078
III 3.21 (2.10–4.90) <0.001 2.93 (1.96–4.39) <0.001
IV 11.44 (6.72–19.32) <0.001 9.15 (5.52–15.15) <0.001
Grade
1 Referent Referent Referent Referent
2 1.61 (0.95–2.75) 0.080 1.53 (0.93–2.49) 0.092
3 3.49 (2.22–5.49) <0.001 2.95 (1.94–4.48) <0.001
Lymphovascular invasion (yes vs. no) 3.00 (2.04–4.42) <0.001 2.81 (1.95–4.04) <0.001
Univariable Cox proportional hazards regression for overall and disease-free survival. TSR was analysed both as a continuous variable (logTSR) and dichotomised
according to the optimised cut-off
Abbreviations: CI confidence interval, FIGO international federation of gynaecology and obstetrics, HR hazard ratio, TSR tumour-stroma ratio
Panayiotou et al. BMC Cancer  (2015) 15:955 Page 4 of 8
of patients stratified according to the optimised TSR
cut-off of 1.3 revealed that high TSR (stroma-low)
tumours were significantly associated with worse OS
(P = 0.009) and DFS (P = 0.015) (Fig. 3). Estimated
five-year cumulative OS and DFS rates were 85 %
and 83 %, respectively, for the TSR-low (stroma-
high) group versus 71 % and 68 %, respectively, for
the TSR-low group. Univariable Cox regression ana-
lysis confirmed that TSR-high tumours (stroma-low)
were associated both with significantly worse OS and
DFS (Table 2). However, TSR did not have independ-
ent prognostic significance in multivariable analysis
when adjustments were made for age, stage, grade,
and lymphovascular invasion (Table 3). Significant
independent prognostic variables for the study cohort
were age, stage, grade and lymphovascular invasion for
OS, and age, stage and lymphovascular invasion for DFS
(Table 3).
TSR associates strongly with tumour grade and the
presence of lymphovascular invasion
Potential associations of TSR with other clinicopatholog-
ical variables were also investigated. After correction for
multiple comparisons, TSR was significantly higher in
grade 3 vs. grade 1 carcinomas (P < 0.001) as well as in
tumours with lymphovascular invasion (P < 0.001). TSR
was also higher in the tumours of patients aged ≥75 years
compared with patients aged <55 years, although this
Fig. 3 Kaplan-Meier survival curves of patients dichotomised according to the optimised TSR cut-off. Kaplan–Meier overall (a) and disease-free
(b) survival curves plus log-rank P-values of patients dichotomised according to a TSR cut-off of 1.3. Numbers at risk for each group are tabulated
below each graph. Abbreviation: TSR = tumour-stroma ratio
Table 3 Multivariable survival analysis of TSR and other prognostic factors
Overall survival Disease-free survival
Factor HR (95 % CI) P HR (95 % CI) P
TSR ( ≥1.30 vs. <1.30) 1.18 (0.56–2.47) 0.667 1.12 (0.57–2.18) 0.740
Age (continuous) 1.07 (1.05–1.09) <0.001 1.06 (1.04–1.08) <0.001
Stage (FIGO 2009)
I Referent Referent Referent Referent
II 1.12 (0.60–2.09) 0.731 1.10 (0.60–2.00) 0.603
III 1.69 (1.07–2.67) 0.024 1.64 (1.06–2.54) 0.028
IV 8.38 (4.75–14.74) <0.001 6.77 (3.92–11.70) <0.001
Grade
1 Referent Referent Referent Referent
2 1.06 (0.61–1.86) 0.835 0.95 (0.57–1.61) 0.857
3 1.96 (1.20–3.21) 0.007 1.61 (1.02–2.55) 0.042
Lymphovascular invasion (yes vs. no) 1.94 (1.26–2.90) 0.002 1.95 (1.30–2.94) 0.001
Multivariable Cox proportional hazards regression for overall and disease free survival
Abbreviations: CI confidence interval, FIGO International Federation of Gynaecology and Obstetrics, HR hazard ratio, TSR tumour-stroma ratio
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association was weaker (P = 0.019). TSR was not signifi-
cantly associated with any other clinicopathological vari-
able, including stage, histopathological subtype, depth of
myometrial invasion, lymph node status or cervical in-
volvement (Table 4). Thus, although high TSR associates
with certain adverse prognostic features in EC, it does
not provide additional prognostic information independ-
ent of these features.
Discussion
The stromal component of epithelial tumours is an area
of intense research, given the importance of the tumour
microenvironment in cancer progression [13, 33]. In this
respect, TSR could be viewed as an indirect measure of
the stromal contribution to malignant progression, as
suggested by studies showing an association between
high tumour stromal content and adverse clinical out-
come in colorectal [14, 17, 22, 25], oesophageal [15, 20],
gastric [34] nasopharyngeal [26] breast (particularly
triple negative) [18, 19, 21, 23] hepatocellular [27], pros-
tate [35] ovarian [16] and cervical [24] cancers. These
results contrast with the findings of the current study,
which demonstrate that high tumour stromal content
(i.e. low TSR) associates with better prognosis in endo-
metrial cancer, both as a continuous variable and when
applying an optimised TSR cut-off. Moreover, the
present data identify highly significant positive associa-
tions between TSR and adverse prognostic features for
EC, namely, grade 3 carcinomas and the presence of
lymphovascular invasion. These observations may ac-
count for the lack of independent prognostic significance
of TSR in EC, but also underscore the association of
high stromal content with good prognosis in this tumour
type. The observation that high stromal content is not a
universal adverse prognostic feature is corroborated by
recently published studies demonstrating low TSR to be
associated with favourable outcome in both oestrogen
receptor positive breast cancer [30] and pancreatic
cancer [36]. The majority of studies investigating the
prognostic significance of TSR have employed visual es-
timation of stromal content, unlike the systematic scor-
ing method applied herein, which could account for
differences in TSR cut-off selection and subsequent out-
come prediction. However, in colorectal cancer, where
both methods have been applied in independent studies,
there is agreement between the systematic scoring
method [17] and conventional visual estimation [14, 22,
25], both in terms of TSR cut-off estimation and prog-
nostic significance.
Reactive stromal formation is a recognised feature of
the inflammatory tumour microenvironment and is
characterised by the presence of cancer associated fibro-
blasts (CAFs), which have been shown to be active
players in tumour progression and metastasis through
Table 4 Association of TSR with other clinicopathological
factors
Factor N (%) TSR, median (IQR) P
All patients 400 (100) 3.3 (2.0–5.3)
Age
<55 56 (14) 3.0 (1.8–4.0)a 0.019
55–64 125 (31) 3.4 (2.0–5.3)a,b
65–74 134 (34) 3.0 (1.9–5.4)a,b
≥75 85 (21) 4.7 (2.5–6.0)b
Stage (FIGO 2009)
I 230 (58) 3.0 (1.8–4.9) 0.192
II 71 (18) 4.0 (2.5–6.6)
III 75 (19) 3.6 (2.1–5.3)
IV 24 (6) 4.8 (2.6–6.2)
Grade
1 149 (37) 2.8 (1.7–4.8)a <0.001
2 106 (27) 3.2 (1.9–4.9)a,b
3 145 (36) 4.1 (2.3–6.0)b
Histology
Endometrioid (EEC) 302 (75.5) 3.2 (2.0–5.1) 1.000
Non–EEC 48 (12) 3.9 (2.2–6.6)
Mixed EEC/non-EEC 50 (12.5) 3.3 (1.9–5.4)
Depth of myometrial invasion
Inner half 210 (52.5) 3.1 (1.7–5.6) 1.000
Outer half 190 (47.5) 3.6 (2.2–5.0)
Cervical involvement
No 261 (65) 3.0 (1.7–5.0) 0.108
Yes 128 (32) 3.7 (2.3–5.4)
Missing data 11 (3) -
Lymph nodes positive
No 274 (68.5) 3.3 (2.0–5.3) 1.000
Yes 50 (12.5) 3.8 (2.2–5.8)
No lymphadenectomy 76 (19) -
Lymphovascular invasion
No 203 (51) 2.9 (1.6–4.8) <0.001
Yes 193 (48) 3.9 (2.2–5.8)
Missing data 4 (1) -
Adjuvant treatment
No 240 (60) 3.2 (1.9–5.2) 1.000
Yes 160 (40) 3.6 (2.1–5.4)
Data were analysed by Mann–Whitney U tests or Kruskal-Wallace tests, as
appropriate. P-values following correction for multiple comparisons (Holm’s
sequential Bonferroni method) are indicated. a,bDepict significant differences
between categories following post-hoc Mann–Whitney U tests
Abbreviations: EEC endometrioid endometrial carcinoma, FIGO international
federation of gynaecology and obstetrics, IQR interquartile range
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their bidirectional interactions with cancer cells (as well
as other cells within the tumour microenvironment)
via cytokine/growth factor mediated signalling and
extracellular matrix remodelling [37–39]. However,
this paradigm may not necessarily apply to all cancer
types. Indeed, recent studies demonstrating a tumour-
suppressive role for CAFs and fibrosis in pancreatic
cancer [40, 41], together with the association of high
tumour stromal content with good prognosis in pan-
creatic cancer reported by Bever and colleagues [36],
suggest that fundamental cancer type-specific differ-
ences in tumour-stroma interactions may exist. Al-
though isolated endometrial CAFs have been found to
promote cancer cell growth [42] or migration [43] in
vitro, a recent study investigating stromal mRNA and
protein expression signatures in EEC found that the
macrophage response signature rather than the acti-
vated stromal signature associated with adverse prog-
nostic features [44]. As yet, the role of the tumour
microenvironment in EC progression is less well stud-
ied than in other common cancers. Clearly, better
characterisation of the EC tumour microenvironment,
including the involvement of the immune effector cell
infiltrate, will be necessary for more accurate prog-
nostication and development of stromal-targeted
therapeutic strategies.
The advantages of this study are its large cohort size
and comparatively long follow-up period. Another ad-
vantage is the use of a digitised scoring method, which
provides a framework for the objective measurement of
TSR. One potential limitation is the heterogeneity of EC
subtypes included in the study. However, TSR was not
found to differ significantly between endometrioid/non-
endometrioid/mixed histology subtypes, thus justifying
such an inclusive approach.
Conclusions
In summary, this study shows that low tumour stromal
content associates both with poor outcome and adverse
prognostic features endometrial cancer, although it is
not independently prognostic. These findings are con-
sistent with the idea that the biology of tumour-stroma
interactions and their prognostic influence are not uni-
versal amongst epithelial tumours.
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